From: A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
Anti-HBs titer (mIU/ml)
Group 1 (N = 25) Hexavac® n (%)
Group 2 (N = 5) Infanrix Hexa® n (%)
p-value
< 10
2 (8.0)
0
1.0000*
10–99
4 (16.0)
2 (40.0)
0.2854**
≥ 100
19 (76.0)
3 (60.0)
-